$DNA

Coen Steven P. sold $6K of DNA

Coen Steven P. (See remarks) sold 752 shares of Ginkgo Bioworks Holdings, Inc. (DNA) at $7.90 on 2026-07-17.

Original reporting
SEC EDGAR · Coen Steven P.
Published Jul 20, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 20, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DNA
Neutral
medium confidence
Mentioned
$DNA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DNANeutralLow
01

Why it matters

The newest fact is the reported open-market sale by an officer, which may slightly influence sentiment but provides no new company performance or guidance information.

02

Market read

Traders may note insider selling as a minor sentiment signal, but the disclosed dollar value is unlikely to be a standalone driver.

03

What to watch

The filing does not state motivations, tax events, or whether other insiders are buying; transaction size is small relative to typical market moves.

Relevance 3/10Novelty 3/10Timing: after-hours filing on 2026-07-20 for a 2026-07-17 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Ginkgo Bioworks Holdings, Inc.

Company-level read

Ticker impact

$DNANeutralMedium confidence
Context

Ginkgo Bioworks insider Coen Steven P sold 752 shares at $7.9030 on 2026-07-17, totaling $5,943.06, per Form 4.

Expected impact

Likely minimal near-term impact; any effect would be limited to incremental sentiment around insider selling.

Evidence & confidence

The filing is primary-source but the transaction size is small and does not include new operational or financial guidance.

Market effects

No direct sector read-across; this is an issuer-specific insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification; the absence of a disclosed 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • Ginkgo Bioworks Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Coen Steven P.

    Officer who sold 752 shares in an open-market transaction.

Related articles

$DNAMed

Ginkgo Bioworks Q2 Earnings Call Highlights

Ginkgo Bioworks (NYSE:DNA) reported first-half 2026 cash burn of $93M, down 3% from $96M a year earlier. Management said Q1 cash burn included a $14M Google Cloud payment tied to an amended 2025 commitment that cut future minimums by over $100M and extended the term to six years. Ginkgo expanded its Nebula lab to 105 racks and raised $17M via an ATM.

$DNAMed

Ginkgo Bioworks Holdings, Inc. (DNA): Results of Operations and Financial Condition

Ginkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991earningspr.htm EX-99.1 Document Exhibit 99.1 Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland Ginkgo provides an update on its second quarter financial

$DNAMed

Researchers are building AI-powered robot labs. What does this mean for science?

NPR reports that Ginkgo Bioworks in Boston is developing an “autonomous lab” where AI directs robots to run experiments, including drug discovery, fertilizer microbes, and protein design. Founders say AI is moving from automating tasks to generating hypotheses, including an OpenAI collaboration using GPT‑5 to design a cell-free protein synthesis reaction. Stanford’s Drew Endy warns of biosecurity and skills-loss risks.

$DNAMed

Researchers are building AI-powered robot labs. What does this mean for science?

NPR reports that researchers at Ginkgo Bioworks in Boston are building “autonomous labs” where AI and robots handle tasks such as pipetting, scheduling experiments, and even generating hypotheses. Founders Jason Kelly and Reshma Shetty say AI is being used to design experiments overnight and to collaborate with OpenAI on cell-free protein synthesis. Stanford’s Drew Endy warns about biosecurity and loss of scientific know-how.